Research ArticleVIROLOGY

Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection

See allHide authors and affiliations

Science Advances  05 Dec 2018:
Vol. 4, no. 12, eaau9812
DOI: 10.1126/sciadv.aau9812


Rift Valley fever virus (RVFV) infections in pregnant livestock cause high rates of fetal demise; miscarriage in pregnant women has also been associated with RVFV infection. To address how RVFV infection during pregnancy causes detrimental effects on the fetus, we developed a pregnant rodent model of RVFV infection. We found that pregnant rats were more susceptible to RVFV-induced death than their nonpregnant counterparts and that RVFV infection resulted in intrauterine fetal death and severe congenital abnormalities, even in pups from infected asymptomatic pregnant rats. Virus distribution in infected dams was widespread, with a previously unrecognized preference for infection, replication, and tissue damage in the placenta. In human mid-gestation placental tissue, RVFV directly infected placental chorionic villi, with replication detected in the outermost syncytial layer. Our work identifies direct placental infection by RVFV as a mechanism for vertical transmission. This is the first study to show vertical transmission of RVFV with a lethal outcome in a species other than livestock. This study highlights the potential impact of a future epidemic of this emerging mosquito-borne virus.


Rift Valley fever (RVF) is a disease of domesticated livestock that is frequently transmitted to humans. RVF virus (RVFV; of the Phenuiviridae family, formerly Bunyaviridae) is currently endemic in many regions of Africa and is transmitted by a range of mosquito species (1). Prominent instances of emergence of RVFV in new areas (such as Egypt in 1977–1978 and Saudi Arabia in 2000–2001) have caused concern for further spread given that mosquito species found in Europe and the Americas could potentially harbor and transmit RVFV (2, 3). The World Health Organization warns of a pending public health emergency caused by RVFV, which would be exacerbated by the lack of U.S. Food and Drug Administration–approved human vaccines and therapeutics and insufficient agricultural vaccines (4).

Epizootic outbreaks of RVF predominantly affect young ruminants such as sheep, goats, cattle, and camels. Within a given outbreak, infected animals succumb to disease characterized by fulminant hepatic necrosis (5). The most notable and economically devastating outcome of RVF is the “abortion storm” that sweeps through herds of pregnant livestock, with abortogenic rates reaching as high as 90 to 100% in pregnant ewes (6, 7). Even live-attenuated veterinary vaccines induce abortions in pregnant animals and cause physical abnormalities in fetuses (810).

In humans, RVF disease is primarily an acute febrile illness accompanied by body aches, joint pain, dizziness, and headaches with occasional progression to hemorrhagic fever with major hepatic involvement, ocular damage, and/or encephalitis. Data from human outbreaks, while limited, suggest that vertical transmission of RVFV to the developing human fetus can occur with detrimental outcomes. Two published cases of vertical transmission resulted in infection and pathological outcomes in the fetuses. In one instance, a pregnant woman became infected with RVFV, resulting in delivery of an infant with rash, enlarged liver and spleen, and jaundice (11). In another family where nine members recently contracted RVF (one of whom died), a pregnant woman showed clinical signs of RVF a few days before labor and delivered an infant who subsequently died of RVF within a week (12). In a recent study in Sudan, pregnant women with confirmed RVF illness during pregnancy had higher rates of second- and third-trimester miscarriages or stillbirths (odds ratio of 7.4) (13).

Given the high incidence of fetal abortions in livestock and the increased risk for miscarriage in RVFV-infected pregnant women, this study addressed vertical transmission of RVFV in non-livestock species and the susceptibility of human placental tissue to RVFV infection. Using immunocompetent Sprague-Dawley (SD) rats infected with a wild-type pathogenic strain of RVFV, we demonstrate direct vertical transmission and intrauterine fetal death similar to that observed in livestock. Vertical transmission occurred in dams that succumbed to disease; notably, vertical transmission also occurred in pregnant dams with no clinical signs of disease, even after infection during late gestation when the placenta is fully formed. Antenatal infection resulted in delivery of stillborn pups with stunted development and gross anatomical changes. It was remarkable that the placenta had a higher viral burden than the liver and other maternal organs, given that the liver typically has the highest titer of RVFV compared to other organs. Ex vivo inoculation of second-trimester human fetal tissue explants with RVFV resulted in active replication in the syncytiotrophoblast layer of the placenta, a structure typically resistant to viral infections (14, 15). This study recapitulates the teratogenic effects of RVFV infection in livestock and is the first rodent model of congenital RVFV to result in fetal demise. In addition, this is the first time RVFV has been shown to directly infect human placental tissue. This study also highlights the previously unrecognized and potentially severe effects of RVFV infection in pregnant women.


Biosafety information

All work with live RVFV was conducted at biosafety level 3 (BSL-3) in the University of Pittsburgh Regional Biocontainment Laboratory (RBL). For respiratory protection, personnel wore powered air-purifying respirators (Versaflo TR-300, 3M) and used a class III biological safety cabinet. All animals were housed in individually ventilated micro-isolator caging (Allentown Inc.). Vesphene IIse (1:128 dilution; Steris Corporation) was used to disinfect all liquid wastes and surfaces at risk of contact with the infectious agent. The RBL is a shower-out facility that requires a full clothing change into scrubs before entry and a personal shower and new scrubs upon exit. All solid wastes, used caging, and animal wastes were steam sterilized. Animal carcasses were incinerated or digested via alkaline hydrolysis (Peerless Waste Solutions). All tissues or samples destined for removal from BSL-3 were inactivated using methods described below; all inactivation methods have been verified and approved by a University of Pittsburgh biosafety oversight committee. The University of Pittsburgh RBL is a registered entity with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture for work with RVFV.

Virus and cell culture

Virulent RVFV strain ZH501, generated from reverse genetics plasmids (16), was provided by B. Miller (CDC, Ft. Collins, CO) and S. Nichol (CDC, Atlanta). Virus was propagated on Vero E6 (CRL-1586, American Type Culture Collection) cells using standard methods. Viral titer was determined by standard viral plaque assay (VPA). Briefly, 200 μl of tissue homogenates or supernatant serially diluted in D2 medium [Dulbecco’s modified Eagle’s medium (DMEM), 2% fetal bovine serum (FBS), and 1% penicillin/streptomycin] was plated on six-well plates (Corning) containing Vero E6 cells at 90 to 95% confluency. Plates were incubated (37°C, 5% CO2) for 1 hour for viral adsorption and rocked every 15 min. Following incubation, the virus inoculum was removed and replaced with 3 ml of agarose overlay [minimum essential medium, 2% FBS, 1% penicillin/streptomycin, 1.5% (1 M) Hepes buffer, and 0.8% SeaKem agarose]. Plates were incubated for 3 days at 37°C, 5% CO2 to allow plaque formation. Plates were treated with 2 ml of 10% formaldehyde for 4 hours for cell fixation and virus inactivation. Plaques were visualized after crystal violet (CV) staining (0.1% CV solution in 20% EtOH) and quantitated using the following equation: Average no. of plaques × 5 (dilution factor) × dilution = plaque forming unit (PFU)/ml.


Age-matched nonpregnant and time-mated SD rats (6 to 8 weeks) were obtained from Envigo Laboratories. A positive copulation plug verified pregnancy for early-gestation [embryonic day 5 (E5)] and late-gestation (E14) females. All pregnant rats were delivered to individual cages, and nonpregnant rats were housed three to a cage in temperature-controlled rooms with a 12-hour day/12-hour night light schedule. Food (IsoPro Rodent 3000) and water were provided ad libitum. Rats were implanted with programmable temperature transponders (IPTT-300, Bio Medic Data Systems) subcutaneously between the shoulder blades. For infection, all rats were anesthetized by inhalation of isoflurane vapors (IsoThesia, Henry Schein) and inoculated subcutaneously in the hind flank with 500 μl of RVFV diluted in D2 medium. Weight and body temperature were recorded daily starting the day of infection. In addition, each animal was closely monitored twice daily for the development of clinical signs. Endpoint criteria, which prompt immediate euthanasia, were defined on the basis of weight, temperature, appearance, and behavioral scoring parameters. Once euthanasia criteria were met, rats were anesthetized by inhalation of isoflurane vapors, followed by an immediate blood draw and euthanasia by cardiac puncture.

Rats were inoculated on E14 with the following doses of RVFV strain ZH501: 7.5 × 101 PFU (n = 5), 1.8 × 102 PFU (n = 6), 1.5 × 103 PFU (n = 11), and 2.6 × 104 PFU (n = 6). Unless dams met euthanasia criteria, they progressed to full-term and delivered pups on E22 [8 days postinfection (dpi)]. After delivery, dams and pups were not disturbed until 5 days postdelivery (13 dpi) to reduce stress. Added stress on the dams can lead to consumption of newborn pups by dam (17). Weight monitoring of pups began on neonatal day 5 (13 dpi) until 18 dpi when both dam and pups were euthanized at the predetermined end of the study (Fig. 1A).

Fig. 1 Pregnant rats are more susceptible to death after RVFV infection, with virus homing to the liver and placenta.

(A) Experimental design for E14 SD rats infected with RVFV. After delivery at E22, dams and pups were not disturbed until 5 days postdelivery (13 dpi). Euthanasia of surviving dams and pups occurred 18 dpi (10 days postdelivery). (B) Survival of RVFV-infected pregnant dams and nonpregnant SD rats (n = 3 to 6 per dose). The shaded area represents the 2- to 6-day clinical window when lethally infected pregnant rats were euthanized owing to severe disease. (C) vRNA (qRT-PCR; left) and infectious virus (VPA; right) in tissues from pregnant rats that succumbed (red squares; n = 17) between 2 and 6 dpi. (D) vRNA in tissue samples from pregnant rats that survived infection (blue circles; n = 11) and were euthanized 18 dpi. Placenta samples (open blue circles) were obtained at day of delivery (8 dpi). (E) Infectious virus measured by VPA in placental samples obtained from lethally infected (red squares) and surviving (blue circles) rats at the indicated dpi. CLN, cervical lymph node. Dotted horizontal lines represent the limits of detection (LOD) of the qRT-PCR (0.1 PFU/ml eq) and VPA (50 PFU). ND, not detected (below the LOD); PFU, plaque-forming unit; PFU/ml eq, PFU per milliliter equivalents; VPA, viral plaque assay; vRNA, viral RNA.

One rat at E5 was infected with 1.5 × 105 PFU of RVFV. A noninfected dam at E5 gestation was observed in parallel. Dams were euthanized at a predetermined date of 7 dpi, corresponding to E13.

Age-matched nonpregnant rats were inoculated with the following doses of RVFV strain ZH501: 3.1 × 103 PFU (n = 11), 3.5 × 104 PFU (n = 5), and 1.3 × 105 PFU (n = 6). Unless the nonpregnant rats met euthanasia criteria and were euthanized, the rats were euthanized at a predetermined end date of the study at 16 dpi.

Upon necropsy, tissues were harvested and suspended in 2× weight/volume D2 media and homogenized using an Omni tissue homogenizer (Omni International). Tissue homogenates were used to quantitate infectious virus by VPA inside the BSL-3 facility. For quantitation of RVFV-specific viral RNA (vRNA) by quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis, 100 μl of each tissue homogenate was inactivated in 900 μl of Tri-Reagent (Invitrogen) for 10 min before removal from the BSL-3 facility. Subsequent storage at −80°C or RNA isolation and qRT-PCR analyses occurred in a BSL-2 setting.

RNA isolation and qRT-PCR

RNA isolation was performed using a modified Invitrogen PureLink Viral RNA/DNA kit protocol. Briefly, 200 μl of chloroform was added to the tissue homogenate/Tri-Reagent, mixed, and then centrifuged at 4°C at 12,000g for 15 min to separate the organic phase from the aqueous phase (contains RNA). The aqueous phase of the cell lysates was collected and then mixed with an equal volume of 70% ethanol, and then the sample was applied to the PureLink spin column. The PureLink Viral RNA/DNA kit protocol, including deoxyribonuclease treatment, was followed for the remainder of RNA isolation procedure. qRT-PCR was performed using the SuperScript III Platinum One-Step qRT-PCR Kit (Invitrogen), following the manufacturer’s guidelines. Primers targeting the RVFV L segment include 5′-TGAAAATTCCTGAGACACATGG-3′ (RVFV-2912Fwd) and 5′-ACTTCCTTGCATCATCTGATG-3′ (RVFV-2912Rev). Taqman probe (RVFV-2950 Probe 5′-CAATGTAA GGGGCCTGTGTGGACTTGTG-3′) was labeled at the 5′ end with the reporter molecule 6-carboxyfluorescein (6-FAM) and quenched internally at a modified “T” residue with BHQ1 (Black Hole Quencher), with a modified 3′ end to prevent probe extension by Taq polymerase. Thermocycling parameters include the following: reverse transcription, 50°C for 30 min; Taq polymerase inhibitor activation, 95°C for 2 min; PCR amplification, 95°C for 15 s; and 55°C for 30 s (40 cycles). Semiquantitation of virus was determined by comparing cycle threshold (CT) values from unknown samples to CT values from the in-house developed ZH501 RVFV RNA standards based on PFU equivalents “PFU/ml eq”.

In situ infection of human tissue

Human placental tissue isolated within the second trimester (14 to 23 weeks) from elective terminations of normal (nongenetically abnormal) pregnancies was obtained from the University of Pittsburgh Health Sciences Tissue Bank through an honest broker system after approval from the University of Pittsburgh Institutional Review Board and in accordance with the University of Pittsburgh anatomical tissue procurement guidelines.

Amnion (fetal membrane), decidua (maternal tissue), and chorionic villi were separated from whole placental tissue and cut to 1 cm by 1 cm sections. Each tissue section was placed in a well of a 24-well plate (Corning) and inoculated with the following doses of RVFV strain ZH501, in duplicate: 1.6 × 107 PFU (n = 2 per donor), 3.0 × 10 6 PFU, 3.0 × 10 5 PFU, 3.0 × 10 4 PFU, or 3.0 × 10 3 PFU (n = 4 per donor unless otherwise stated). Five hundred microliters of virus diluted in D2 media was added to each tissue and incubated in a 37°C incubator for 1 hour for viral adsorption. The inoculum was removed, washed twice with phosphate-buffered saline (PBS), and then replaced with 1 ml of complete growth medium (DMEM/F12, 10% FBS, 1% penicillin/streptomycin, and amphotericin B). To generate a viral growth curve, 50 μl was collected from each tissue every 12 hours for 48 hours and analyzed by qRT-PCR. Forty-eight hours after infection, all supernatant was collected, and tissues were washed two times with PBS and then fixed in 4% paraformaldehyde (PFA) for 24 hours for fluorescent microscopy imaging. Tissues or supernatant was analyzed in quadruplicate; two of these tissues were processed for fluorescent microscopy.

Fluorescent microscopy

Human tissue was fixed in 4% PFA for 24 hours at 4°C, washed in 1× PBS, and then permeabilized with 0.25% Triton X-100 in 1× PBS for 30 min at room temperature with gentle agitation. Tissue was washed and then incubated with antibodies to double-stranded RNA [dsRNA; recombinant J2, as described previously (14)] and rabbit anti–cytokeratin-19 (Abcam) and counterstained with actin (using Alexa Fluor–conjugated phalloidin) for 1 hour at room temperature. Following washing with 1× PBS, tissue was incubated with Alexa Fluor–conjugated secondary antibodies (Invitrogen), washed, and then mounted with Vectashield (Vector Laboratories) containing 4′,6-diamidino-2-phenylindole (DAPI). Images were captured using a Zeiss LSM 710 inverted laser scanning confocal microscope and contrast adjusted in Photoshop. Quantification of the extent of RVFV infection was performed using Fiji (National Institutes of Health). Regions of interest of the syncytium from four different donors were defined using Fiji, and the extent of RVFV infection (as assessed by the relative fluorescent units) was quantified. In total, 11 villi were quantified from uninfected controls and 16 villi were quantified from RVFV infected tissue.


For fixation of tissues and inactivation of virus, tissues were submerged for 24 hours in 4% PFA at 4°C. Before removal from the BSL-3 laboratory, 4% PFA was replaced with fresh 4% PFA. In the BSL-2 laboratory, 4% PFA was removed and washed from tissue with 1× PBS, submerged in PBS, and stored at 4°C until processed further. Tissues were paraffin embedded, and sections were cut onto slides following standard histological processes by the University of Pittsburgh McGowan Institute Histology Core.

Whole pups were submerged in 4% PFA for 24 hours. To ensure complete inactivation, pups were cut in half laterally and then exposed to 4% PFA for another 24 hours before removal from the BSL-3 laboratory. Half pups were further cut into whole head and abdomen sections in the BSL-2 laboratory before embedding in paraffin and cut onto slides.

Slides were deparaffinized using an alcohol rehydration series and then stained following standard hematoxylin and eosin (H&E) staining procedures. For immunohistochemistry, fixed slides were deparaffinized using an alcohol rehydration series and boiled in 10 mM citric acid buffer (pH 6.0) to unmask antigen-binding epitopes. Primary antibody was IBT Bioservices Rift Valley fever MP12 antibody (catalog no. 04-001); secondary antibody was Vector Laboratories biotinylated horse anti-rabbit (H+L) (catalog no. BA-1000). Chromogen staining for visualization was carried out using a Vector Laboratories Vector Blue Alkaline Phosphatase Substrate kit according to the manufacturer’s instructions. Slides were imaged using the Nikon 90i Eclipse epifluorescent microscope provided by the University of Pittsburgh Center for Biologic Imaging.


Statistical analysis was performed using Graphpad Prism 7.0. Survival of pup and dams was compared using Mann-Whitney U test. Growth curve of pups 7 and 8 from dam 4 was calculated using linear regression modeling. Intensity of RVFV immunostaining in uninfected and infected human placental tissue was compared using a t test.


Susceptibility of late-gestation pregnant SD rats to RVFV disease and death

Rats develop severe disease after RVFV infection, similar to the severe liver pathology often observed in domesticated livestock and occasionally in humans (18, 19). We have previously used rats to study different disease outcomes resulting from RVFV infection (18, 20). Although there are notable morphologic differences between the placentas of humans and rodents, rats are often used to study placental development, embryogenesis, embryotoxicity, and vaccine teratogenicity during pregnancy (2123). The fully intact placenta forms a physical barrier between the mother and fetus, facilitates nutrient exchange, and protects the developing fetus from microbial invasion. The gestational period for rats is 22 days, and by E14, the placenta is fully formed with deep trophoblast invasion within the uterine wall (21).

For these studies, time-mated SD rats at E14 were infected with the pathogenic ZH501 strain of RVFV by subcutaneous injection in the hind flank (Fig. 1A). As controls, age-matched, nonpregnant rats were similarly infected. Some rats developed severe disease as a result of infection, and in these cases, euthanasia endpoint criteria were met within 2 to 6 dpi in both pregnant and nonpregnant groups (Fig. 1B). Rats that survived infection had few signs of disease and delivered pups on E22. Surviving pups were not handled until 5 days postdelivery, after which they were weighed daily. Surviving dams and pups were euthanized at the end of the study (neonatal age of 10 days; 18 dpi) (Fig. 1A).

The pregnant rats were more susceptible to death after infection than their nonpregnant counterparts (Fig. 1B). Nonpregnant rats survived infection despite exposure to high doses of RVFV (only 2 of 22 died; 9%), whereas 57% of pregnant rats died (16 of 28) when exposed to even low doses of RVFV (P = 0.0008). Within the pregnant rat cohort, there was no association between death after infection and the administered dose (P = 0.321).

Reproductive tissues are targets of RVFV infection in pregnant and nonpregnant rats

The distribution of virus throughout the tissues was measured by qRT-PCR and/or VPA in pregnant rats that succumbed to lethal disease (2 to 6 dpi; Fig. 1C), pregnant rats that survived (18 dpi; Fig. 1D), and their nonpregnant counterparts (16 dpi for survivors; fig. S1, A and B). Infectious virus was widely distributed throughout the animals that succumbed, regardless of pregnancy status. In surviving animals at 18 dpi, infectious viral burden was not detected in both pregnant and nonpregnant rats. vRNA, however, remained widely distributed in the survivors at the end of the study, 18 dpi (Fig. 1D). As expected, because RVFV is a hepatotropic virus, the liver contained large amounts of infectious virus in lethally infected rats (pregnant and nonpregnant; Fig. 1C and fig. S1B), and large amounts of vRNA remained in the liver of survivors at 18 and 16 dpi, respectively (Fig. 1D and fig. S1A).

Placental samples were available from the pregnant rats that succumbed to disease and a few that survived (most surviving rats consumed the placenta at the time of delivery and were not available for analysis; Fig. 1E). The placenta contained high levels of infectious virus measured by plaque assay regardless of the time after infection. Even the placentas obtained from the surviving rats on the day of delivery contained extraordinary amounts of infectious virus, with one animal having over 109 PFU/ml.

In addition to the placenta, the uterus, ovary, and amniotic sac contained infectious virus in the lethally infected rats (Fig. 1C), and vRNA persisted in these tissues in survivors (Fig. 1D). Virus was also found in the mammary glands (four of five rats had detectable vRNA and one had infectious virus), indicating that vertical transmission of RVFV from dam to pup could possibly occur through lactation. There is a concern that consumption of raw milk from goats and cattle may be a risk for human infection with RVFV (24).

Compared to controls, histology sections of livers from lethally infected pregnant (Fig. 2) and nonpregnant (fig. S1C) rats displayed a reproducible pattern of tissue injury that included widespread sinusoidal congestion, multifocal recent hemorrhage, massive hepatocyte necrosis, and acute inflammation. These are classic histological findings in animals infected with RVFV (25). In addition, the livers of infected rats had high levels of RVFV antigen (fig. S1, D and E). Together, our data suggest that both pregnant and nonpregnant rats succumb to infection following massive liver necrosis, although pregnant rats are more susceptible to developing disease after exposure to low levels of virus compared to nonpregnant rats (Fig. 1B).

Fig. 2 RVFV causes pathology within the liver, uterus, and placenta of pregnant dams.

H&E staining within the indicated tissues. (A) Images (20×) of liver, uterus, and placenta. (B) Images (60×) of placenta. Blue, white, yellow, orange, and green arrowheads highlight evidence of hemorrhaging, necrosis, vascular/perivascular congestion, calcification, and nucleated red blood cells, respectively.

The placentas from lethally and sublethally infected dams displayed a reproducible pattern of tissue injury that included multifocal necrosis and recent hemorrhage in the decidua and trophospongiosum, vascular congestion and massive necrosis of parenchymal cells within the labyrinth, and an acute intravascular and perivascular inflammatory infiltrate associated with intraplacental arteries (Fig. 2, A and B). A discernible increase in circulating nucleated red blood cells was also seen.

Within lethally infected dams, necrotic lesions were found within the uterus (Fig. 2A). Several pregnant dams that survived infection had subserosal nodules within the myometrium of the uterus that showed evidence of liquefactive necrosis, acute inflammation, and calcification. Despite the presence of vRNA and infectious RVFV within the ovaries of both nonpregnant (fig. S1, A and B) and pregnant (Fig. 1, C and D) RVFV-infected rats, reproducible histopathological changes were not observed.

RVFV vRNA was also found in the testes of infected male Lewis rats (fig. S2). The levels of RVFV vRNA and infectious particles found here in the uterus, ovary, placenta, amniotic sac, mammary glands, and testes, as well as the histological damage in certain tissues, demonstrate that RVFV has a previously unappreciated preference for targeting the reproductive tissues.

Direct vertical transmission of RVFV to pups during late gestation results in pup deformity and demise

Within the pregnant dams that succumbed to RVFV infection at 2 to 6 dpi, virus was widespread throughout various tissues, corroborating the pantropic nature of RVFV (Fig. 1C). Within the corresponding pups from these dams that died, qRT-PCR of the peritoneal cavity or brains also detected high levels of vRNA (Fig. 3A). Vertical transmission occurred while the pups were in utero, as the dams were euthanized before delivery.

Fig. 3 Infection of pregnant dams results in direct transmission of RVFV to the peritoneum and brain of pups.

Pups delivered from (A) lethally infected and (B) surviving pregnant rats were tested for vRNA within the peritoneal cavity (left) and brain (right). In (A), the x axis represents the day the dams were euthanized owing to severe disease. In (B), the x axis represents the day after delivery, with day 10 representing surviving pups euthanized at the end of the study. For both graphs, red square data points indicate pup demise and blue circle data points indicate pup survival. Open data points are pup brain tissues; all closed data points are pup peritoneal cavity. (C) Photographic evidence of fetal resorption within the uterus of one of three dams that succumbed to RVFV infection. (D) Images (10×) of whole pups were examined for histological changes. H&E staining of a whole pup from a dam that succumbed to infection (right) or a corresponding uninfected control rat (left) euthanized at the same day of gestation. Blue, white, and black arrowheads highlight evidence of hemorrhaging, necrosis, and altered intestinal structure, respectively.

Because most humans develop nonlethal febrile illness when infected with RVFV, we were interested in the outcome of the pups from dams that survived infection with few to no clinical signs. Many of the pups born from these surviving, clinically normal dams were dead at delivery or shortly thereafter (Fig. 3B). Of 10 pregnant dams that survived infection and reached full-term (E22), all gave birth to at least one pup that died either due to infection or consumption on the days following delivery. An additional dam survived to full-term; however, all pups were consumed by this dam and were unable to be recorded for analysis.

The 11 infected dams gave birth to a total of 111 pups, 39 of which survived (35.1%). In comparison, of the eight uninfected control dams, 66 of 88 (75.0%) pups survived to the end of the study (P < 0.0001). Dams are known to eat their young owing to stress (such as the laboratorian disturbing the pups to weigh them after delivery) or if they notice abnormalities (17). Some of the uninfected dams consumed their pups during this study; thus, the survival rate of the pups from uninfected dams can be considered the baseline for these experimental conditions. The average survival rate of pups per litter delivered by infected dams was 27.2%, whereas uninfected rats were 2.45 times more likely to survive (66.8%, P = 0.02). Outcomes from four specific dam cases are presented and discussed in the following section.

Overall, we detected very high levels of vRNA (106 to 107 PFU/ml eq) in the peritoneal cavity of stillborn pups birthed by dams that had no apparent clinical disease (Fig. 3B). It is quite notable that the virus was vertically transmitted and replicated to high levels in the pups while causing no clinical disease in the dam herself. vRNA was also detected in the brains of pups from both surviving and lethally infected dams (Fig. 3, A and B). Fetal resorption is characteristic of vertical transmission in animals infected with viruses such as Zika virus (26) and vesicular stomatitis virus (27). Evidence of fetal resorption occurred in three lethally infected dams exposed to RVFV during late-stage gestation (Fig. 3C and fig. S3).

H&E sections of whole pups from lethally infected dams showed significant liver damage (massive parenchymal necrosis, vascular congestion, and areas of recent hemorrhage; Fig. 3D). Pups also displayed altered intestinal structure compared to pups from uninfected dams.

During the late stages of pregnancy, RVFV is directly transmitted to the developing pups, resulting in increased rates of death and tissue damage. This is not an all-or-nothing phenomenon within individual litters, as we found that physical changes and survival varied within the same litter. To illustrate this, four selected cases are described below.

Description of individual dam cases. Dam 1 reached full-term gestation with no apparent clinical signs or significant liver damage, yet she still died giving birth (8 dpi). Dam 1 delivered 11 pups that were all dead upon delivery, with 2 pups remaining within the uterus at the time of her demise (Fig. 4A). Like other RVFV-infected dams, vRNA was widespread throughout the dam’s tissues (Fig. 4B). Because this dam died during delivery, the placenta was available to directly compare the virus burden of the placenta to other maternal tissues harvested at the same time. In the other cases discussed below, the dams ate placentas after birth, so they were unavailable to sample. Notably, at the time of death, dam 1 had 107 PFU/ml of virus in the placenta, which is 4 logs more vRNA than the liver and spleen, the primary targets of the virus (Fig. 4B). In addition, the uterus and ovary had about 1 log more vRNA than the liver and spleen, demonstrating a preference for RVFV to replicate within reproductive tissues.

Fig. 4 Vertical transmission of RVFV in two dams resulted in stillborn pups with physical abnormalities and high viral titers.

(A to D) Dam 1 was inoculated with 175 PFU and died giving birth at 8 dpi. Dam 1 delivered 13 stillborn pups, with 2 remaining in the uterus. (A) Pictures of individual pups are shown as numbered. Uterus with pups 13 and 14 within birth canal after demise. (B) vRNA within maternal tissue. (C) vRNA and (D) infectious virus within peritoneal cavity of indicated pups. The three pups not included in the graphs were used for other analyses. (E to H) Dam 2 was inoculated with 175 PFU and survived with no clinical signs of disease. Dam 2 delivered seven pups to full-term; five were dead and two were alive but subsequently consumed by the dam (data not available). (E) Pictures of individual pups as labeled. A normal pup from an uninfected dam is shown for comparison. (F) vRNA within maternal tissue. (G) vRNA and (H) infectious virus within peritoneal cavity of indicated pups. For all graphs, red square data points indicate either dam or pup demise. Blue circle data points indicate dam or pup survival.

The stillborn pups from dam 1 had apparent gross abnormalities (small, rounded head and gray discoloration) and variable size (1.5 to 3 cm) compared to uninfected pups (5 cm; Fig. 4A). Nine of the 11 pups (82%) had abnormally shaped heads compared to uninfected pups. Pups 6 and 7 likely died earlier in utero, as indicated by their small size and apparent decomposition; both of their heads were disproportionately large owing to early gestational demise. While the other pups were larger than pups 6 and 7, none of them were normal in size, and they were all born deceased. The pups had very high levels of vRNA (106 to 107 PFU/ml eq, irrespective of pup size; Fig. 4C). Less infectious virus was recovered from the pups compared to vRNA (Fig. 4, C and D), likely due to the inability to preserve tissue immediately after death because pups succumb to infection in utero or shortly after delivery. This trend is observed for all representative dams (Figs. 4 and 5); otherwise, RVFV infectivity correlates very closely with qRT-PCR results as seen in Fig. 1.

Fig. 5 Evidence of variable survival and developmental outcome of pups resulting from vertical transmission.

(A to E) Dam 3 was inoculated with 175 PFU and survived with no clinical signs of disease. Dam 3 delivered 10 pups to full-term; 6 were dead and 4 were alive. Two living pups were consumed by the dam within 2 days of birth (data not available). Two remaining pups survived to the end of the study (pups 7 and 8). (B) vRNA within maternal tissue. (C) vRNA and (D) infectious virus within peritoneal cavity of indicated pups. (E) Weight of surviving pups from dam 3 from days 5 to 10 neonate. The black line and the gray line represent growth curve calculated by linear regression modeling of pups 7 and 8, respectively. (F to J) Dam 4 was inoculated with 1300 PFU and survived with no clinical signs of disease. Dam 4 delivered nine stillborn pups. (F) Pictures of individual pups as labeled. (G) vRNA within maternal tissue. (H) vRNA and (I) infectious virus within peritoneal cavity of indicated pups. (J) Cage of dam 4 as it was found on day of pup delivery (E22; 8 dpi).

Dam 2 survived infection with no apparent clinical signs. vRNA was still detected throughout the dam at 18 dpi, with the highest burden in reproductive tissues and the brain (Fig. 4F). At E22, she delivered seven pups; five were born dead and two were alive. Both living pups were consumed by the dam within a day of birth. Dams periodically eat their young because of stress or if they notice abnormalities in their pups (17). The pups shown in Fig. 4E are around 5 cm in length, which is normal for full-gestation pups. Several have dark-colored bodies, likely signifying decomposing tissue and/or blood congealment. Smaller, rounded heads without a pointed snout were observed in three of the seven pups (pups 2, 3, and 5). Despite pup 1 having physical features and length similar to those of a normal pup delivered from an uninfected mother (Fig. 4E), vRNA and infectious virus were highest in this pup compared to its littermates that had more severe gross anatomical abnormalities (Fig. 4, G and H). This may be due to more advanced decomposition setting in pups 2, 3, and 5 that affected virus infectivity.

In another case, dam 3 also survived infection with no clinical signs of disease and had widespread vRNA in tissues at 18 dpi (Fig. 5B). She delivered 10 pups at full-term (E22); 6 pups were born deceased and 4 were alive. Two of the living pups survived until the scheduled euthanasia date (18 dpi; 10 days neonate), whereas the other two were consumed by the dam within 2 days postdelivery. Pups 1 and 2 from dam 3 were relatively normal in appearance; however, they were born deceased and displayed the highest vRNA (Fig. 5C) and infectious virus (Fig. 5D) burden compared to littermates with physical abnormalities; this could be due to the more recent demise of pups 1 and 2, which preserved infectious virus until tissue was collected. The pups that die earlier in utero likely have less infectious virus due to decomposition, which affects virus viability. Despite pups 7 and 8 surviving until planned euthanasia at neonatal age of 10 days with no signs of disease or gross abnormalities, vRNA was still detected in the peritoneal cavity of these pups, although infectious virus was not found (Fig. 5, C and D). Pup 7 weighed significantly less than its littermate, and both had similar growth rates (slope = 1.88 for pup 7 and slope = 2.26 for pup 8; P = 0.14) after birth (Fig. 5E). It is unclear whether this is natural variation in pup size or an effect of viral infection in utero.

Last, dam 4 had no signs of clinical disease and delivered a total of nine deceased pups at full-term (Fig. 5F). Multiple pups were found encapsulated in an amniotic sac and/or still connected to a placenta (Fig. 5J). Placenta collected the day of delivery had high levels of vRNA (105 PFU/ml eq); the vRNA levels in the placenta were similar to that found in the pups, regardless of pup size (Fig. 4, H and I). Seven of nine pups (78%) had abnormally shaped heads compared to uninfected pups. The pups had gross abnormalities and varied in color from pink to gray to black. Infectious virus was detected in five of nine pups (Fig. 4I). The smallest pup (pup 11) measured at about 2.2 cm, while the largest pup from the litter was about 4.1 cm in length; all pups from this litter were still smaller than pups delivered from uninfected dams (typically 5 cm).

The four dams highlighted above, despite being asymptomatic, had liquefactive myonecrosis within the uterus (Fig. 2). The placenta also had notable abnormalities, including inflammation, cell necrosis, and hemorrhage in the decidua and villous structures (Fig. 2, A and B).

Vertical transmission of RVFV in an early-gestation pregnant rat

To examine the potential for vertical transmission of RVFV before the development of a fully formed placenta, an early-gestation (E5) SD dam was infected with 1.5 × 105 PFU of RVFV. An uninfected, age-matched, pregnant dam served as a control. At 7 dpi, corresponding to E13, neither dam had clinical signs of disease, and both dams underwent planned euthanasia (fig. S4A). The observed virus distribution in the early-gestation pregnant rat resembled that of the late-gestation pregnant rats (fig. S4B and Fig. 1). Infectious virus was detected in the cervical lymph node, spleen, liver, and placenta, with the placenta containing 3 logs more infectious virus than the spleen (106 PFU/ml versus 103 PFU/ml, respectively; fig. S4B). Because of the small size of each embryo at this gestational age, embryonic tissue from the entire litter was pooled and analyzed for the presence of vRNA and infectious particles (fig. S4C). Pooled embryos had 2 logs more vRNA and infectious virus than the spleen of the dam (106.5 PFU/ml versus 103 PFU/ml, respectively).

At the time of euthanasia, the uninfected dam had a healthy uterus containing 14 embryos, all with similar sizes, shapes, and a translucent pale yellow coloring. Of the 16 embryos of the infected dam, 4 (25%) were red in color (fig. S4D) instead of the pale yellow coloring observed in the remaining 12 embryos and embryos of the uninfected control (fig. S4D, left). Three embryos were smaller than the embryos from the rest of the litter. They lacked amniotic fluid and were palpably dense and hard in appearance (fig. S4D, embryos 4 to 6); embryos 4 and 5 were two of the four red in color. The red coloring and rigid appearance and structure of embryos from infected dams suggest early hemorrhaging and/or resorption of the embryos. These results show that RVFV is vertically transmitted to embryos of dams infected during early gestation, with a preferential niche within the placental tissue.

Replication of RVFV in human placental tissue

Although two isolated cases of vertical transmission have been reported in humans from Africa and the Middle East (11, 12) and a single study highlighted the potential of RVFV-infected women to be four times more likely to have a late miscarriage or stillbirth (13), the effect of RVFV infection on the developing human fetus is not known. To evaluate whether human fetal tissue is permissive to RVFV infection and replication, placental chorionic villi were obtained from healthy human donors undergoing elective termination at 16 to 23 weeks of gestation (second trimester). Tissues were inoculated in vitro with RVFV, and explant supernatant was collected every 12 hours for measurement of viral replication. Similar viral growth kinetics was seen in chorionic villi from two different donors (Fig. 6A); 2 to 3 log increase in virus production was detected between 12 and 36 hours after infection.

Fig. 6 RVFV replicates in human placental tissue, even the highly resistant syncytiotrophoblasts within placenta villi.

Human chorionic villous tissue explants from donors 1 and 2 (A) were infected in vitro with RVFV at the indicated doses and then the supernatant was harvested at 0, 12, 24, 36, and 48 hours after infection for measurement of vRNA by qRT-PCR. (B) Immunofluorescent microscopy images of villi infected with 3 × 106 PFU RVFV for 48 hours. Uninfected control is shown on the left. DAPI (blue) stains DNA, J2 antibody (green) stains dsRNA of RVFV, cytokeratin 19 (red) stains epithelial cells, and actin (purple) stains all cells. (C) Fluorescent dsRNA signal was quantified from four human donors. Data from uninfected (n = 11) and infected (n = 16) villi are shown with symbols stratified by donor (closed circles, donor 1; open circles, donor 2; closed squares, donor 3; open squares, donor 4). **P < 0.01.

To identify the cell type(s) targeted by RVFV in placental villi, we performed immunostaining for dsRNA as previously described (14). Viral replication, as assessed by the production dsRNA, was evident in the villi, with replication observed in both the syncytial layer and the subsyncytial layers within mononuclear cytotrophoblasts (Fig. 6B). Significantly higher levels of dsRNA signal were detected in infected villi from four different donors compared to uninfected villi from the same donors (Fig. 6C). These data suggest that RVFV exhibits tropism for human placental tissue and can replicate to some degree in syncytiotrophoblasts, which are known to resist many viruses (28).


Viral infections in pregnant women can have adverse effects on both the mother and the developing fetus. Pregnant women are likely to have more severe pathology, more serious complications, and an increased risk of death compared to nonpregnant women (29). For both seasonal and pandemic influenza, pregnant women are more susceptible to developing severe complications requiring hospitalization (30, 31). Other emerging viruses, such as Ebola and Lassa, are also more severe or deadly in pregnant women (32, 33). Here, we found pregnant rats to be more susceptible to severe disease and death after RVFV infection than their nonpregnant counterparts. Necrosis of the liver was characteristic of disease in both pregnant and nonpregnant rats, indicating that pregnancy did not alter the disease presentation but rather made the pregnant animals more susceptible to severe disease overall.

A 1987 study of pregnant women in Mozambique showed that women with miscarriage or stillbirth had the same prevalence of RVFV-specific immunoglobulin G (IgG) antibodies as women with normal deliveries (34). However, detection of IgG antibodies is indicative of past exposure to RVFV and not necessarily acute infection during pregnancy. In a more recent cross-sectional study in Sudan, there was a significant association between RVFV infection during pregnancy and miscarriage (13). Of the women with confirmed RVFV infections and disease during pregnancy, 54% had miscarriage compared to 12% in uninfected women. RVFV infection was an independent predictor of miscarriage (odds ratio of 7.4); all of these miscarriages occurred in the second and third trimesters (13). While this is only one study, it strongly implicates RVFV infection as a causative agent of miscarriage in late gestation. Miscarriage earlier in pregnancy due to RVF may also occur but remain underreported.

Two cases of vertical transmission of RVFV were documented in Saudi Arabia (2000) and Sudan (2007) (11, 12). In both cases, onset of RVF-like illness in the mothers occurred around 37 to 38 weeks of gestation. In the 2 weeks before illness in the Saudi woman, six family members developed RVF-like illness and one died of confirmed RVF. The woman developed RVF-like symptoms 4 days before delivery of a full-term infant at home. On the second day of life, the infant was hospitalized with respiratory distress, jaundice, and lethargy. He died 6 days after admission with hemorrhagic signs and an enlarged liver. In the Sudanese patient, labor commenced within 10 days of illness onset, and an infant was born with skin rash, palpable liver and spleen, and an Apgar score of 5. Samples from the mother and cord blood tested positive for RVFV IgM. The outcome of this infant is not known. Together, these data suggest that RVFV infection is associated with adverse pregnancy outcomes during the second and third trimesters. Vertical transmission and miscarriage due to RVFV infection early in pregnancy may be easily overlooked; therefore, vertical transmission during the first trimester should not be disregarded.

To our knowledge, this is the first study to discover the degree to which RVFV targets reproductive tissues and causes catastrophic pathology. The ovaries, uterus, and placenta are previously unrecognized sites of virus replication in both pregnant and nonpregnant animals. A previous study in mice found virus-infected macrophages within the stroma of ovaries from immunodeficient animals infected with an attenuated strain of RVFV (35). Here, we found high levels of infectious virus and vRNA in the reproductive tissues, and the placenta and uterus displayed histological changes associated with viral infection. Liquefactive necrosis within the uterus of the four dams profiled was notable. Uterine cell death may be a contributing factor to premature placental detachment and intrauterine fetal death within RVFV-infected dams. In addition, the tissues with the highest viral burden were the liver and placenta of both lethally and sublethally infected pregnant dams. Further studies should be performed to understand the onset and progression to fetal demise and elucidate commonalities between the liver and placental structure that accommodates comparable pathology after RVFV infection.

The most alarming and arresting finding from our study was the delivery of dead pups from dams that survived RVFV infection, appeared otherwise clinically normal, and gave birth at normal gestation length. The pups displayed physical abnormalities that resembled hydrops fetalis, which is an abnormal accumulation of fluid in the fetus. Hydrops fetalis is seen in RVFV-infected livestock (36) and has been noted as a prominent occurrence in pregnant women infected with parvovirus and Zika (37, 38). Most humans infected with RVFV develop mild febrile disease, and our study suggests that mild infection of pregnant women may still have devastating impacts on the developing fetus.

A previous study in mice inoculated pregnant dams 3 to 4 days before term with a mouse-passaged strain similar to the Smithburn live vaccine strain (39). Variable levels of virus were detected in embryos taken from sick dams, and the authors state that no abortions were observed. It is not clear whether all of the dams died as a result of infection and whether any delivered live pups.

In contrast, we observed heterogeneous survival and developmental outcomes of pups delivered by RVFV-infected dams. Some dams gave birth to both live and dead pups, and within the dams that delivered only dead pups, there was variation with the size and gross abnormalities seen within pups from the same litter, indicating that infection, growth restriction, developmental abnormalities, and/or death did not occur simultaneously or with the same outcome. Further studies will determine the specific developmental effects that RVFV infection in utero has on the developing fetus.

Our work demonstrates the lethal effects of RVFV in pregnant rats. However, given that the human and rodent placenta differ at both the morphologic and cellular levels, which may influence vertical transmission, we also performed studies in human tissue isolated from mid-gestation. This gestational age represents a stage in which RVF-induced fetal death has been observed in humans (13). Our studies revealed that RVFV can replicate to a high degree in human chorionic villi, which resist infection by other viruses, including Zika virus (14, 15). Immunofluorescence analysis showed that viral replication occurred in both the outermost syncytial layer and subsyncytial layers such as cytotrophoblasts. Of note, we have shown previously that human placental syncytiotrophoblasts are highly resistant to viral infections through their constitutive release of antiviral molecules including type III interferons (IFNs) (15). We have also shown that the syncytium expresses high levels of IFN-stimulated genes (ISGs) under basal states, suggesting that these IFNs protect the syncytium from viral infections in an autocrine manner. Our data thus suggest that RVFV may be insensitive to placenta-derived type III IFNs, perhaps through mechanisms that suppress the activity of ISGs or the response of the syncytium to type III IFNs.

Ruminants have multicotyledonary, epitheliochorial placentas, while both humans and rodents have discoid hemochorial placentas (21, 40). Despite some similarities, the placental structure differs between rats and humans in many ways. Humans have a placental-fetal interface consisting of villous trophoblasts with extravillous trophoblastic cells, while rats have a labyrinth zone with invasive trophoblasts (21). Although livestock have placental structures different from those of rodents and humans, our data suggest that the mechanism by which RVFV is vertically transmitted can be shared among eutherian mammals, with specific tropism for fetal-derived placental cells. Our study thus provides a framework for understanding vertical transmission of RVFV that is applicable to both veterinary and human context. Comparison of these models could also explain the potentially disparate rate of miscarriages between livestock and humans.

While the abortogenic effect of RVFV in pregnant livestock is historically well known, the mechanisms underlying these observations are not. The teratogenic potential of live-attenuated vaccine candidates is assessed in pregnant sheep, despite the lack of data on the basic mechanism of vertical transmission of wild-type virus (810). Our findings here are noteworthy because this is the first time direct vertical transmission through the placenta resulting in fetal death has been demonstrated in a species other than livestock. Because the ability to test vaccines in livestock is expensive and limited to only a few facilities able to perform these types of experiments, evaluation of vertical transmission in rats would be very useful. Vaccine candidates could be screened for adverse effects in pregnant rats before evaluation in pregnant ewes.

This study provides insights into the vertical transmission potential of RVF in humans and highlights the need for more epidemiological data from human outbreaks to understand the effect of RVFV infection in pregnant women. The existing data, combined with what is known to occur in livestock and our work presented here, point to the high likelihood that RVFV can have damaging effects on fetuses in humans. Emergence of RVFV beyond its current locations due to changing climate, altered mosquito habitats, and/or accidental introduction would present a significant risk to pregnant women. Future work aimed at defining teratogenic potential of RVF in humans is critical to design strategies to reduce the potential for fetal disease in pregnant women, who may themselves display few clinical symptoms.


Supplementary material for this article is available at

Fig. S1. RVFV is present in the ovary and uterus of nonpregnant female rats.

Fig. S2. Detection of RVFV in the testes of male rats.

Fig. S3. RVFV infection leads to fetal resorption.

Fig. S4. Evidence of vertical transmission of RVFV in an RVFV-infected early-gestation (E5) pregnant dam, with high viral titers in the placenta.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.


Acknowledgments: We express our gratitude for the technical assistance provided by A. Walters, advice on experimental design from J. Lundy and R. Walker, rat art provided by H. Ma, and study coordination by S. Barrick. We also thank the Center for Biologic Imaging and the McGowan Center for Regenerative Medicine for histology support. Funding: This work was partially supported by the University of Pittsburgh Center for Vaccine Research (to A.L.H.), NIH R01-NS101100-01A1 (to A.L.H.), R21-NS088326 (to A.L.H.), NIH R01-AI081759 (to C.B.C.), R01-HD075665 (to C.B.C.), a Burroughs Wellcome Investigators in the Pathogenesis of Infectious Disease Award (C.B.C.), and the Children’s Hospital of Pittsburgh of the UPMC Health System (to C.B.C.). We also acknowledge the Tissue and Research Pathology Services/Health Sciences Tissue Bank, which receives funding from P30CA047904. Ethics statement: All animal work described here was carried out in strict accordance with the Guide for the Care and Use of Laboratory Animals of the NIH and the Animal Welfare Act. The protocol was approved and overseen by the University of Pittsburgh Institutional Animal Care and Use Committee. The Association for Assessment and Accreditation of Laboratory Animal Care has fully accredited the University of Pittsburgh. Author contributions: C.M.M., C.B.C., and A.L.H. conceived the study and designed the experiments; C.M.M., N.A., D.A.B., J.R.A., and M.R.K. performed experimental work; J.F.B. contributed pathology expertise and interpretation; C.M.M., C.B.C., and A.L.H. analyzed and interpreted the data; C.M.M. and A.L.H. wrote the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.
View Abstract

Navigate This Article